ST. PETERSBURG, Fla., Sept. 9, 2011 /PRNewswire/ -- The Advanced Wound Management division of Smith & Nephew (LSE: SN; NYSE: SNN) today announced results from 11 studies on a range of products and therapies from their ALLEVYN*, ACTICOAT*, IODOSORB* and RENASYS* wound care portfolio. The data demonstrate advanced healing strategies and the efficacy of the company’s specialized advanced wound care products. Results of the studies are being presented at the Clinical Symposium on Advances in Skin & Wound Care (CSASWC), a national convention for wound care professionals.
(Photo: http://photos.prnewswire.com/prnh/20110909/SF65366)
The results of the IODOSORB trial will be shared as a podium presentation. This was a prospective, non-comparative, multicenter study investigating the effect of IODOSORB on bioburden load and other wound characteristics in diabetic foot ulcers. Elevated bacterial burden has been cited as a contributing factor in the delayed healing of these types of ulcers. The study showed significant evidence (p=0.008) of reduction in the clinical signs of infection when IODOSORB was used.
“The study results showed that when IODOSORB was used on diabetic foot ulcers, significant reductions in wound area, levels of exudates and pain were seen in patients, as well as an improvement in wound appearance,” said Dr. John Lantis II, Chief of Division, Endovascular-Vascular Surgery, Director of Clinical Research, Department of Surgery, St. Lukes-Roosevelt Hospital Center, New York and author of the research. “This is encouraging news for patients, as foot ulcers occur in nearly 15 percent of all patients with diabetes.”
In addition to the new clinical data being presented at CSASWC, Smith & Nephew will also introduce the new ALLEVYN Gentle Border Multisite dressing. Its imaginative shape is designed to fit the unique contours of the body, and stay in place. ALLEVYN Multisite, along with ALLEVYN Gentle Border Sacrum and ALLEVYN Gentle Border Heel are uniquely shaped dressings that form the foundation for the new ‘Human Shaped Wound Care’ campaign. As part of the campaign introduction, Smith & Nephew will be hosting an interactive ALLEVYNGentle BorderMultisite Challenge, at their booth (#225).
“Reducing the human and economic cost of wounds is a core value of Smith & Nephew. We are focused on innovation and best practice techniques for the prevention and healing of wounds. Imaginative solutions like our new Human Shaped ALLEVYN dressings help improve outcomes for patients and at the same time conserve resources for health care systems,” said Thomas J. Dugan, President of Smith & Nephew’s North American Advanced Wound Management Division.
Additionally, Smith & Nephew will be offering Twin Towers Pins to attendees, for a $2 donation to the Twin Tower Orphan fund. The program was founded on September 11, 2001 with the sole purpose of providing educational and welfare assistance to the children who lost parents by the terrorist attacks on 9/11.
Smith & Nephew will continue its presence at tradeshows throughout the fall at:
- Diabetic Limb Salvage conference (Sept. 22-24)
- The American Society of Plastic Surgeons meeting (Sept. 23-27)
- The Symposium of Advanced Wound Care (Oct. 13-15)
- The Orthopedic Trauma Association annual meeting (Oct. 12-15)
- Health Industry Distributers Association Conference & expo (Oct. 19-21)
- The Canadian Association of Wound Care annual conference (Nov. 3-6).
To get the latest and timeliest news from the Advanced Wound Management division of Smith & Nephew, register at www.Twitter.com today and “follow” @woundcare.
About Smith & Nephew
Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy, including Sports Medicine; and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people’s lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company has distribution channels, purchasing agents and buying entities in over 90 countries worldwide. Annual sales in 2010 were nearly $4.0 billion.
Forward-Looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
* Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Advanced Wound Management division of Smith & Nephew